Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
In my opinion age has nothing to do with it, f they have the experience and nous they can broker any sized deal. In regards to licensing Tyk2 pre-clinical it can still achieve a large deal as Tyk2/JAks are becoming more popular since the Celgene deal earlier this year. If I remember correctly Tim mentioned a pre-clinical deal for a company in the US for $800m in a proactive investor interview and has been gunning for something similar ever since- the finals RNS I believe was Sar's confirmation of the type deal(s) they want and I think they are now looking at billions, but what do I know, I can only read between the lines like everyone else. The Chk1 milestone for sure will be a catalyst for the share-price no doubt but also security for Sar to fight for a bigger deal as they will have the funds to further validate Tyk2 even take it to ph1.
I'm convinced the NEDS are here to help wind down the company. The age of the NEDS is another pointer IMO. Runoff mode is the term Thoth used, an insurance term but I get what he meant. They may be helping to secure a deal but being non-execs they are perfectly placed for caretaking roles. Target price and date is anyone's guess but I still believe getting a CHK1 milestone will be the catalyst to get things moving. This is the reason, IMO, that we won't get the true value for the TYK2 compounds. It's too early to sell TYK2 but we have taken as far as we can. Once TYK2 is in P1, it'll be time to start the wind-down.
Stoney - many thanks, really interesting and informative.
In the context of Sierra and 737 one would expect Nick Glover to be well versed in the licencing process and to have been getting his ducks lined up for some time....given the November Nasdaq deadline if the non-dilutive options have not been set up by then Sierra will be in deep misery.
In respect of Sareum, if the CHK1 deal negotiations were handled by CPF/CRT with Sareum on the periphery their experience will be limited which may not bode well for TYK2. I have real anxiety that we are going to at worst fail or at best not fully realise the value of 1801/2 due to lack of experience/expertise. Tim and John are clearly very capable scientists and have invested many years in getting Sareum to where it is today however they probably don't have the business acumen necessary to bring the baby home. Parker is along for the ride and is more focussed on MGC Pharmaceuticals, Glyndebourne, Brexit and Surrey carpet bowls association, Michael Owen is 67 and probably winding down, Clive Birch is 65....
Hi Krone - this is an interesting read on Pharma deals.
https://cdn.ymaws.com/www.michbio.org/resource/resmgr/BioToolBox_-_Commercialization/Bio_Pharma_Partnering.pdf
Thoth. What is your thoughts on target price?
Thoth2 - how long from expression of interest to conclusion of sub-licence deal? Presumably the lawyers involved are doing these deals all the time. For Sierra there must be a real urgency given gone potentially imminent Nasdaq delisting.
Ramblings from me.
Pfizer dropped their chk1 as it didn't meet primary endpoint in ovarian. According to endpoints 5 days ago.
We are dosing at higher levels as less toxic. But srra are deprioritising. Suggests our data in ovarian is not overwhelming.
Combo data still to come
Combo with parps and wee1 looking very viable Merck. Azn . Jansen in the mix
Srra has limited cash.
And a pathway to fast track in anogenital but srra dont want to front a 20m milestone for a subset of indications. I dont know how this will play out. But obviously on the radar/involved with several big pharma. My expectation is sublicences. Azn for a wee1 combo. Merck for a keytruda combo. Jansen for a niraparib in breast. And crt to cofund an anogenital trial. But as usual I may be blowing smoke up my own arse for which I apologise
Let’s not get carried away ... one step at a time people please ... and forwards please TM